In a Phase @ , randomized , double-blind , double-dummy study ( NCT@ ) , patients ( low-density lipoprotein cholesterol -LSB- LDL-C -RSB- @-@ mg/dL , @-year risk of fatal cardiovascular events @ % - < @ % -LSB- systemic coronary risk estimation -RSB- ) were randomized to ezetimibe @mg/day ( n = @ ) or alirocumab @ mg subcutaneously ( via @-mL autoinjector ) every @ weeks ( Q@W ) ( n = @ ) , with dose up-titrated to @ mg Q@W ( also @ mL ) at week @ if week @ LDL-C was @ mg/dL .